Literature DB >> 32608295

Low-dose vemurafenib monotherapy in BRAFV600E -mutated Erdheim-Chester disease.

Gordon J Ruan1, Antonious Hazim1, Jithma P Abeykoon1, Caleb Scheckel1, Robert Vassallo2, Jay H Ryu2, W Oliver Tobin3, Matthew J Koster4, N Nora Bennani1, Karen L Rech5, Jason R Young6, Mithun V Shah1, Gaurav Goyal7, Ronald S Go1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32608295      PMCID： PMC8023000          DOI： 10.1080/10428194.2020.1783447

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  8 in total

1.  Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).

Authors:  Fleur Cohen Aubart; Jean-François Emile; Fabrice Carrat; Frédéric Charlotte; Neila Benameur; Jean Donadieu; Philippe Maksud; Ahmed Idbaih; Stéphane Barete; Khê Hoang-Xuan; Zahir Amoura; Julien Haroche
Journal:  Blood       Date:  2017-06-30       Impact factor: 22.113

2.  Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Authors:  Ankush Bhatia; Gary Ulaner; Raajit Rampal; David M Hyman; Omar Abdel-Wahab; Benjamin H Durham; Ahmet Dogan; Neval Ozkaya; Mario E Lacouture; Julio Hajdenberg; Chezi Ganzel; Eli L Diamond
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

3.  Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.

Authors:  Julien Haroche; Fleur Cohen-Aubart; Jean-François Emile; Philippe Maksud; Aurélie Drier; Dan Tolédano; Stéphane Barete; Frédéric Charlotte; Philippe Cluzel; Jean Donadieu; Neïla Benameur; Philippe A Grenier; Sophie Besnard; Jean-Paul Ory; François Lifermann; Ahmed Idbaih; Brigitte Granel; Bruno Graffin; Baptiste Hervier; Laurent Arnaud; Zahir Amoura
Journal:  J Clin Oncol       Date:  2014-11-24       Impact factor: 44.544

Review 4.  Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.

Authors:  Sarah J Welsh; Pippa G Corrie
Journal:  Ther Adv Med Oncol       Date:  2015-03       Impact factor: 8.168

5.  Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.

Authors:  Gaurav Goyal; Mark L Heaney; Matthew Collin; Fleur Cohen-Aubart; Augusto Vaglio; Benjamin H Durham; Oshrat Hershkovitz-Rokah; Michael Girschikofsky; Eric D Jacobsen; Kazuhiro Toyama; Aaron M Goodman; Paul Hendrie; Xin-Xin Cao; Juvianee I Estrada-Veras; Ofer Shpilberg; André Abdo; Mineo Kurokawa; Lorenzo Dagna; Kenneth L McClain; Roei D Mazor; Jennifer Picarsic; Filip Janku; Ronald S Go; Julien Haroche; Eli L Diamond
Journal:  Blood       Date:  2020-05-28       Impact factor: 22.113

6.  Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Authors:  Eli L Diamond; Vivek Subbiah; A Craig Lockhart; Jean-Yves Blay; Igor Puzanov; Ian Chau; Noopur S Raje; Jurgen Wolf; Joseph P Erinjeri; Jean Torrisi; Mario Lacouture; Elena Elez; Ferran Martínez-Valle; Benjamin Durham; Maria E Arcila; Gary Ulaner; Omar Abdel-Wahab; Bethany Pitcher; Martina Makrutzki; Todd Riehl; José Baselga; David M Hyman
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

7.  Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease.

Authors:  Gaurav Goyal; Mithun V Shah; Timothy G Call; Mark R Litzow; William J Hogan; Ronald S Go
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777

Review 8.  Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease.

Authors:  Ila M Saunders; Aaron M Goodman; Razelle Kurzrock
Journal:  Oncologist       Date:  2019-11-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.